|
WO2021075526A1
|
|
Method for producing fusion protein of serum albumin and growth hormone
|
|
WO2021039644A1
|
|
QUANTIFICATION METHOD OF Hex4, lyso-GM1, Fuc-GlcNAc-Asn, AND lyso-sulfataide INCLUDED IN CEREBROSPINAL FLUID
|
|
WO2020235543A1
|
|
Nucleic acid molecule used for production of recombinant aav virion
|
|
WO2020040071A1
|
|
Analytical method for chondroitin sulfate
|
|
CA3103769A1
|
|
Method for producing dental pulp-derived cells
|
|
WO2020004368A1
|
|
Protein-containing aqueous liquid formulation
|
|
JP2020036580A
|
|
Analysis software and apparatus for screening early embryo
|
|
CN111683972A
|
|
Methods for delivering agents to muscle
|
|
EP3712609A1
|
|
Analysis method for glycan having acid group
|
|
US2021061918A1
|
|
Aqueous pharmaceutical composition
|
|
JP2019060837A
|
|
Method for analyzing glycosaminoglycan
|
|
WO2018124277A1
|
|
Lyophilized preparation
|
|
WO2018043399A1
|
|
Novel therapeutic agent for diabetes
|
|
WO2018038243A1
|
|
Method for producing antibody fusion protein
|
|
WO2017159540A1
|
|
Serum albumin-20 k growth hormone fusion protein
|
|
US2019078129A1
|
|
Method for production of mutant-type human erythropoietin
|
|
CN108369050A
|
|
Mobile low-temperature workbench
|
|
JP2017062234A
|
|
Quantification method of polysorbate
|
|
KR20180042432A
|
|
New human serum albumin variant
|
|
CN107849555A
|
|
Pass through the anti-human transferrin receptor antibody of blood-brain barrier
|
